Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
GEOVAX LABS INC (GOVX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.16-5.95%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GOVX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
successful capital raising through private placements | The company is actively raising funds through private placements. | Under Pressure | failure to raise adequate capital or excessive dilution news | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage biotechnology, not a proven durable compounder. The long-term thesis is intact, but evidence of delivery on key clinical priorities is mixed and confidence in the assessment is medium.
The valuation evidence points to GOVX being cheap versus peers, but confidence in that comparison is low. The valuation measure has fallen substantially, while the evidence does not show how much clinical progress or future results the market already assumes.
Near term, losses continued in the first half of 2026, and cash was roughly unchanged from year-end 2025; the supplied results do not show that the GEO-MVA study has started. The next-quarter miss risk is elevated, while a guidance cut and weakening jobs data are risks; recent financial performance is described as neutral and in the top half of the industry.
Over the multi-year view, the key test is whether management moves GEO-MVA from study-readiness work into meaningful clinical progress and provides evidence on Gedeptin strategies. Near term, guidance and cash discipline matter; sector momentum could help, while weaker employment or a guidance cut could weigh on the business setup.
For the next one to three years, GOVX remains a high-risk, loss-making clinical-stage story with an intact but weakly evidenced thesis. Progress on clinical programs and careful management of limited cash are central. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in GEOVAX LABS INC's published investment case. The stated target is EPS loss narrows toward zero. |
| Improving |
| EPS loss widens or remains flat beyond FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
progress in M&A activity through definitive agreements | A supporting condition in GEOVAX LABS INC's published investment case. The stated target is complete accretive M&A deals to enhance operations. | Under Pressure | lack of meaningful M&A progress or failed deals | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.07 → $-2.64 · observed estimates
$0.52B → $0.52B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.07 | $519,556,799 | 1 / 1 |
| 2026-07-25 | $-3.07 | $519,556,799 | 1 / 1 |
| 2026-07-26 | $-3.07 | $0 | 1 / 1 |
| 2026-07-27 | $-3.07 | $519,556,799 | 1 / 1 |
| 2026-07-28 | $-3.07 | $519,556,799 | 1 / 1 |
| 2026-07-29 | $-3.07 | $0 | 1 / 1 |
| 2026-07-30 | $-3.07 | $0 | 1 / 1 |
| 2026-07-31 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-01 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-02 | $-2.85 | $0 | 2 / 1 |
| 2026-08-03 | $-2.85 | $0 | 2 / 1 |
| 2026-08-04 | $-2.85 | $0 | 2 / 1 |
| 2026-08-05 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-06 | $-2.85 | $0 | 2 / 1 |
| 2026-08-07 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-08 | $-2.85 | $0 | 2 / 1 |
| 2026-08-09 | $-2.85 | $0 | 2 / 1 |
| 2026-08-10 | $-2.85 | $0 | 2 / 1 |
| 2026-08-12 | $-2.85 | $0 | 2 / 1 |
| 2026-08-13 | $-2.85 | $0 | 2 / 1 |
| 2026-08-14 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-15 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-16 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-17 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-18 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-19 | $-2.85 | $519,556,799 | 1 / 1 |
| 2026-08-20 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-21 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-22 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-23 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-24 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-25 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-26 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-27 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-28 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-29 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-30 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-08-31 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-09-01 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-09-02 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-09-03 | $-2.85 | $519,556,799 | 2 / 1 |
| 2026-09-04 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-05 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-06 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-07 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-08 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-09 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-10 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-11 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-12 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-13 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-14 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-15 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-16 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-17 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-18 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-19 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-20 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-21 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-22 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-23 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-24 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-25 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-26 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-27 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-28 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-29 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-09-30 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-01 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-02 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-03 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-04 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-05 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-06 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-07 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-08 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-09 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-10 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-11 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-12 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-13 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-14 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-15 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-16 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-17 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-18 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-19 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-20 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-21 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-22 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-23 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-24 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-25 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-26 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-27 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-28 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-29 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-30 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-10-31 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-11-01 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-11-02 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-11-03 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-11-04 | $-2.64 | $519,556,799 | 2 / 1 |
| 2026-11-05 | $-2.64 | $519,556,799 | 2 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.